Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring
-
Published:2020-06-19
Issue:1
Volume:24
Page:
-
ISSN:1364-8535
-
Container-title:Critical Care
-
language:en
-
Short-container-title:Crit Care
Author:
Susen SophieORCID, Tacquard Charles Ambroise, Godon Alexandre, Mansour Alexandre, Garrigue Delphine, Nguyen Philippe, Godier Anne, Testa Sophie, Levy Jerrold H., Albaladejo Pierre, Gruel YvesORCID, Albaladejo P., Blais N., Bonhomme F., Borel-Derlon A., Cohen A., Collet J.-P., de Maistre E., Fontana P., Huet D. Garrigue, Godier A., Gruel Y., Godon A., Ickx B., Laporte S., Lasne D., Llau J., Le Gal G., Lecompte T., Lessire S., Levy J. H., Longrois D., Madi-Jebara S., Mansour A., Mazighi M., Mismetti P., Morange P. E., Motte S., Mullier F., Nathan N., Nguyen P., Pernod G., Rosencher N., Roullet S., Roy P. M., Schlumberger S., Sié P., Steib A., Susen S., Tacquard C. A., Testa S., Vincentelli A., Zufferey P., Borel-Derlon A., Boissier E., Dumont B., de Maistre E., Gruel Y., James C., Lasne D., Lecompte T., Morange P. E., Nguyen P., Siguret V., Susen S.,
Abstract
AbstractCOVID-19 is an infection induced by the SARS-CoV-2 coronavirus, and severe forms can lead to acute respiratory distress syndrome (ARDS) requiring intensive care unit (ICU) management. Severe forms are associated with coagulation changes, mainly characterized by an increase in D-dimer and fibrinogen levels, with a higher risk of thrombosis, particularly pulmonary embolism. The impact of obesity in severe COVID-19 has also been highlighted.In this context, standard doses of low molecular weight heparin (LMWH) may be inadequate in ICU patients, with obesity, major inflammation, and hypercoagulability. We therefore urgently developed proposals on the prevention of thromboembolism and monitoring of hemostasis in hospitalized patients with COVID-19.Four levels of thromboembolic risk were defined according to the severity of COVID-19 reflected by oxygen requirement and treatment, the body mass index, and other risk factors. Monitoring of hemostasis (including fibrinogen and D-dimer levels) every 48 h is proposed. Standard doses of LMWH (e.g., enoxaparin 4000 IU/24 h SC) are proposed in case of intermediate thrombotic risk (BMI < 30 kg/m2, no other risk factors and no ARDS). In all obese patients (high thrombotic risk), adjusted prophylaxis with intermediate doses of LMWH (e.g., enoxaparin 4000 IU/12 h SC or 6000 IU/12 h SC if weight > 120 kg), or unfractionated heparin (UFH) if renal insufficiency (200 IU/kg/24 h, IV), is proposed. The thrombotic risk was defined as very high in obese patients with ARDS and added risk factors for thromboembolism, and also in case of extracorporeal membrane oxygenation (ECMO), unexplained catheter thrombosis, dialysis filter thrombosis, or marked inflammatory syndrome and/or hypercoagulability (e.g., fibrinogen > 8 g/l and/or D-dimers > 3 μg/ml). In ICU patients, it is sometimes difficult to confirm a diagnosis of thrombosis, and curative anticoagulant treatment may also be discussed on a probabilistic basis. In all these situations, therapeutic doses of LMWH, or UFH in case of renal insufficiency with monitoring of anti-Xa activity, are proposed.In conclusion, intensification of heparin treatment should be considered in the context of COVID-19 on the basis of clinical and biological criteria of severity, especially in severely ill ventilated patients, for whom the diagnosis of pulmonary embolism cannot be easily confirmed.
Publisher
Springer Science and Business Media LLC
Subject
Critical Care and Intensive Care Medicine
Reference35 articles.
1. Chan KW, Wong VT, Tang SCW. COVID-19: an update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-Western Medicine for the management of 2019 novel coronavirus disease. Am J Chinese Med. 2020;48(3):737–62. 2. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–7. 3. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, Lee M. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state. JAMA. 2020. https://doi.org/10.1001/jama.2020.4326. 4. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. Jama. 2020. https://doi.org/10.1001/jama.2020.5394. 5. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020. https://doi.org/10.1001/jama.2020.4683.
Cited by
119 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|